Riskpilot← Back to searchSign inGet full accessValeos Pharma A/S
A/SActiveCVR 39696614Østervej 2Manufacture of basic pharmaceutical products · NACE 2110Est. 201820 employees
Revenue 2024
DKK -3,8M
-34% vs 2023
EBITDA margin
374.5%
+3% vs 2023
Equity ratio
11.7%
Financial strength
Net profit 2024
DKK -16,9M
-2% vs 2023
| Revenue | DKK -3,8M | -34% |
| EBITDA | DKK -14,4M | +3% |
| Net profit | DKK -16,9M | -2% |
| Total assets | DKK 58,1M | -5% |
| Equity | DKK 6,8M | +181% |
| Employees | 20 | — |
Legal name
Valeos Pharma A/S
CVR number
39696614
Legal form
Aktieselskab
NACE code
2110 · Manufacture of basic pharmaceutical products
Founded
3. juli 2018
Share capital
DKK 802.635
Employees
20 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren sammen med bestyrelsesformanden eller af den samlede bestyrelse.
Company purpose
Virksomhedens formål er at dyrke medicinsk cannabis og hermed beslægtede produkter og hermed beslægtet virksomhed
Address
Østervej 2
Phone
+4520651018
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -318 | -1.277 | -3.379 | -6.489 | -5.839 | -3.847 |
| Staff expenses | -4 | -702 | -4.014 | -6.837 | -9.039 | -10.559 |
| EBITDA | -322 | -1.979 | -7.393 | -13.326 | -14.877 | -14.405 |
| Depreciation & amort. | -0 | -0 | -20 | -54 | -2.354 | -3.114 |
| EBIT | -322 | -1.979 | -7.413 | -13.380 | -17.231 | -17.519 |
| Net financials | -0 | -194 | -797 | -1.256 | -3.937 | -4.182 |
| Profit before tax | -322 | -2.173 | -8.209 | -14.637 | -21.168 | -21.701 |
| Tax | -71 | -468 | -1.801 | -3.211 | -4.634 | -4.756 |
| Net profit | -251 | -1.705 | -6.408 | -11.426 | -16.534 | -16.945 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 1.081 | 22.247 | 49.945 | 57.322 | 61.095 | 58.144 |
| Equity | 289 | -1.416 | 16.532 | 5.106 | -8.428 | 6.800 |
| Long-term debt | 650 | 22.235 | 31.108 | 34.710 | 46.510 | 29.671 |
| Short-term debt | 142 | 1.428 | 2.300 | 17.498 | 23.013 | 20.518 |
| Total debt | 792 | 23.664 | 33.408 | 52.208 | 69.523 | 50.190 |
EBITDA margin
-1440542000.0%
This company
15.8%
Market median
-9117354530% vs market
20192024
Equity ratio
11.7%
This company
38.2%
Market median
-69% vs market
20192024
Return on equity
-249.2%
This company
18.4%
Market median
-1454% vs market
20192024
Net profit margin
-1694471000.0%
This company
8.1%
Market median
-20919395162% vs market
20192024
Asset turnover
-0.07×
This company
1.12×
Market median
-106% vs market
20192024
Debt / equity
7.55×
This company
0.62×
Market median
-1118% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-07-03 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BS Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
FJ Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
PF Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
ML Chief Executive Officer | Chief Executive Officer | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
MSG Capital APS | Company | 50.0% | 50.0% | 2024 |
A. Rosen Holding ApS | Company | 15.0% | 15.0% | 2024 |
Kleingut ApS | Company | 10.0% | 10.0% | 2024 |
Novosato Holding ApS | Company | 20.0% | 20.0% | 2020 |
Henriksholm 2018 ApS | Company | 5.0% | 5.0% | 2021 |
| Individual | 20.0% | 20.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
A. Rosen Holding ApS
Valeos Pharma A/S Board members of Valeos Pharma A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Birgitte Steen Frydland | Chief Executive Officer | 0 companies |
| Farzad Jahanshahi | Chief Executive Officer | 0 companies |
| Peter Frederik Andreasen | Chief Executive Officer | 0 companies |
| Morten Larsen Snede | Chief Executive Officer | 0 companies |
| Henrik Kristian Moltke | Chairman | 0 companies |
| Glenn Steven Nielsen | Chairman | 0 companies |
| Kristian Schrøder Hart-Hansen | Board of Directors | 0 companies |
| Michael Halborg-Bendtsen | Board of Directors | 0 companies |
| Michael Andreasen | Board of Directors | 0 companies |